Anti-PD-1/PD-L1 therapy for renal cell carcinoma: challenges in the development of predictive biomarkers.

Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial. Based on these results, PD-L1 expression on tumor cells is not widely used as a biomarker for anti-PD-1/PD-L1 therapy in RCC patients. Keywords: anti-PD-1/PD-L1 therapy; biomarker; renal cell carcinoma; PD-L1 expression; peripheral blood biomarkers EN anti-PD-1/PD-L1 therapy biomarker renal cell carcinoma PD-L1 expression peripheral blood biomarkers 667 669 3 07/05/22 20220701 NES 220701 1. Significance of PD-L1 expression on tumor as a biomarker Expression of PD-L1 on tumor cells facilitates cancer immune evasion. [Extracted from the article]